Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Actelion Ltd.
Headquarters: Allschwil, Switzerland
Website: N/A
Year Founded: 1997
Status: Acquired
BioCentury | Jan 13, 2025
Deals
Lilly catches Relay in PI3Ka race via Scorpion acquisition
A spinout will house precision oncology assets from Scorpion
BioCentury | Oct 25, 2024
Deals
James Sabry on industry-shaping changes in innovation and deal-making
Business development veteran talks to BioCentury as he transitions from Roche to BioMarin, entering the one biotech segment he’s not yet been in
BioCentury | May 21, 2024
Management Tracks
Clozel looks to next chapter as Idorsia chair
CFO André Muller to succeed Clozel as CEO
BioCentury | Dec 7, 2023
Finance
Dec. 7 Quick Takes: Radiopharma play ARTbio bolsters team with $90M, Novartis vets
Plus: Regeneron’s bispecific heading to FDA and updates for Vanda, J&J, Merck, Ipsen, Genfit
BioCentury | Dec 6, 2023
Management Tracks
Catalyst hires Michael Kalb as CFO
Plus: Raab to become Amicus chair when Crowley heads to BIO and updates from AC Immune, Gossamer Bio, Chimerix, Versameb, Alzheon, Kling and Avalere
BioCentury | Sep 8, 2023
Deals
Sept. 7 Quick Takes: Seagen, Nurix in deal to create degrader-antibody conjugates
Plus: U.K. rejoins Horizon Europe and more from Mariana, Corteria, Noetik, CymaBay, J&J, Alnylam and BlueWhale
BioCentury | Sep 7, 2023
Deals
Idorsia’s hypertension lifeline
Swiss biotech Idorsia hopes near-term commercial opportunity for aprocitentan will spur investors to refinance the company
BioCentury | Jun 21, 2023
Deals
June 20 Quick Takes: FDA approves argenx’s subcutaneous Vyvgart
Plus: Clozel provides Idorsia cash lifeline, a clinical hold for Arcellx and updates from Vera, Denali, Delve Bio and Turbine
BioCentury | May 31, 2023
Management Tracks
Simon Jose to leave Idorsia
Plus: Vadsholt to leave Orphazyme and updates from Quibim, Mithra and Phanes
BioCentury | Oct 6, 2022
Management Tracks
LifeMine rounds out team with Stahl, Plamondon
Plus Theolytics adds Actelion vet Oakley as CFO, and updates from Capricorn, Cambrian,
Items per page:
1 - 10 of 814